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Background: Surfactant protein D (SP-D), a pattern recognition molecule, has been shown to play roles in host
defense such as opsonisation, aggregation of pathogens, and modulation of the inflammatory response. In light of
infection-induced exacerbations and damage to the airway epithelium from inflammation, these functions of SP-D
make it relevant in the development and pathogenesis of asthma.
Methods: Expression of SP-D was examined in human airway sections and primary airway epithelial cells (AEC)
grown in air-liquid interface (ALI) cultures and comparisons were made between those from asthmatic and
non-asthmatic donors. ALI cultures of AEC from non-asthmatic donors were examined for SP-D, Mucin 5AC, and
cytokeratin-5 expression at different stages of differentiation. Interleukin-13 (IL-13) treatment of airway epithelium
and its effect on SP-D expression was studied using ALI and monolayer cultures of primary AEC from non-asthmatic
and asthmatic donors.
Results: Airway epithelium of asthmatics, compared to that of non-asthmatics, expressed increased levels of SP-D as
demonstrated in airway tissue sections (fraction of epithelium 0.66 ± 0.026 vs. 0.50 ± 0.043, p = 0.004) and ALI cultures
(fraction of epithelium 0.50 ± 0.08 vs. 0.25 ± 0.07). SP-D expression decreased as ALI cultures differentiated from 7 days
to 21 days (fraction of epithelium 0.62 ± 0.04 to 0.23 ± 0.03, p = 0.004). Treatment with IL-13 decreased SP-D expression
in both ALI cultures (fraction of epithelium 0.21 ± 0.06 vs. 0.62 ± 0.04, p = 0.0005) and monolayer cultures (protein
expression fold change 0.62 ± 0.05) of non-asthmatic AEC; however, IL-13 had no significant effect on SP-D expression
in monolayer cultures of asthmatic AEC. Experiments with non-asthmatic monolayer cultures indicate IL-13 exert its
effect on SP-D through the IL-13 receptor alpha1 and transcription factor STAT6.
Conclusions: SP-D is expressed differently in airways of asthmatics relative to that of non-asthmatics. This can have
implications on the increased susceptibility to infections and altered inflammatory response in asthmatic patients.
Future functional studies on the role of SP-D in asthma can provide better insight into defects in the structure and
regulation of SP-D.
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Asthma is a chronic inflammatory disorder of the airways
which affects people of all ages. It has increased in preva-
lence over the past 30 years and currently affects 235 million
people worldwide [1]. Clinically, asthma is characterized by
recurrent and reversible episodes of wheezing, chest tight-
ness, breathlessness, and coughing. Structural and functional
changes associated with asthma include bronchoconstric-
tion, airway inflammation, epithelial goblet cell hyperplasia,
bronchial smooth muscle hypertrophy, and proliferation of
airway blood vessels and nerves [2]. Higher proportion of
basal cells as opposed to differentiated cells has also been
found in airways of asthmatics [3].
Asthmatic patients may have increased susceptibility to
viral and bacterial infections in the airways. Respiratory
viral infections have detrimental effects on patients with
established asthma; they have been associated with almost
80% of asthma exacerbations [4]. Respiratory syncytial
virus (RSV) is the most common cause of acute lower re-
spiratory infection in infants and children worldwide [5].
Several studies have demonstrated an association of severe
RSV infection in infancy with subsequent development of
recurrent wheezing and asthma in children [6-9]. Asthma
has traditionally been closely associated with the adaptive
immune system; however, more recent studies have indi-
cated that the innate immune response is also important
in its development and progression [10]. Therefore, the
role of the innate immune system in host defence against
inhaled pathogens and subsequent inflammatory response
is of particular interest.
Pulmonary surfactant was originally identified as a lipo-
protein complex which reduces surface tension in the
alveoli. More recently, the surfactant proteins A and D
(SP-A, SP-D), were found to be involved in host defense
mechanisms [11]. SP-A and SP-D, belong to the collectin
family of proteins and are pattern recognition molecules
which bind a broad spectrum of pathogens including vi-
ruses, bacteria, and fungi [11]. Its roles in host defense in-
clude enhancement of phagocytosis through opsonisation,
aggregation of pathogens, and regulation of inflammatory
mediators [11]. SP-A and SP-D are constitutive mediators
of antigen clearance which can interact with cellular com-
ponents of both innate and adaptive immune system on
the mucosal surface [12].
Interleukin-13 (IL-13) is a cytokine secreted by many
cell types including TH2 cells, macrophages, and activated
mast cells [13-15]. Several animal models have indicated
that IL-13 mediates features of asthma such as airway
hyper-reactivity, mucus cell hyperplasia, and sub-epithelial
airway fibrosis independent of other cytokines [13,16,17].
The role of IL-13 in mediating phenotypes of asthma was
also supported by reports of increased IL-13 in lungs of
asthmatic patients [18]. IL-13 has two receptors: IL-13
receptor alpha 1 (IL-13Rα1) and IL-13 receptor alpha 2(IL-13Rα2). IL-13Rα1 forms a heterodimeric receptor
complex with IL-4Rα subunit. IL-13 signalling via
IL-13Rα1 activates the Janus kinase (JAK)-signal trans-
ducer and activator of transcription (STAT) pathway,
specifically the transcription factor STAT6. IL-13Rα2
is known as a high-affinity receptor and can signal via
the transcription factor, activator protein 1[19].
The present study aims to characterize the expression of
SP-D in airways of asthmatics, with the hypothesis that it
would differ from that of non-asthmatics. The effects of
differentiation and IL-13 exposure on the expression of
SP-D were investigated using air-liquid interface (ALI) cul-
tures of primary airway epithelial cells (AEC) from non-
asthmatic donors and monolayer cultures of AEC from
non-asthmatic and asthmatic donors.
Material and methods
Reagents
Mouse anti-human SP-D antibody used for immunohisto-
chemistry (IHC) and Western blot analysis (catalog no.
HYB-245-01-02) was purchased from Thermo Scientific
(Rockford, IL). Mouse anti-β-actin monoclonal antibody
conjugated to horseradish peroxidase (sc-47778) was pur-
chased from Santa Cruz Biotechnology (Santa Cruz, CA).
Mouse anti-Mucin 5AC (MUC5AC) antibody (AB24071)
and rabbit anti-cytokeratin 5 (CK-5, AB24647) antibody
were purchased from Abcam Inc. (Toronto, ON) for IHC.
Recombinant human IL-13 (213-IL), goat anti-human
IL-13Rα1 (AF-152) and IL-13Rα2 (AF-146) neutralizing
antibodies and normal goat IgG (AB-108-C) were pur-
chased from R&D Systems (Minneapolis, MN). Mouse
anti-phosphorylated STAT6 (p-STAT6) antibody (611566)
and mouse anti-STAT6 antibody (611290) used for Western
blotting were purchased from BD Biosciences (Mississauga,
ON). Trizol reagent (15596018) was purchased from
Life Technologies (Burlington, ON).
Cell culture
Human lungs of de-identified asthmatic and non-
asthmatic donors, deemed unsuitable for transplant-
ation and donated to medical research, were obtained
from the International Institute for the Advancement
of Medicine (Edison, NJ) for primary cell isolation as
per approval by the Research Ethics Board (REB) of
University of British Columbia/Providence Healthcare
(REB# H00-50110). Airway epithelial cells (AEC) were
isolated by protease digestion as described by Gray and
colleagues [20], cultured in bronchial epithelial growth
medium (Lonza, Mississauga, ON, CC-3170), incubated at
37°C in 5% CO2, and grown in 12-well plates. Treatment of
primary AEC in monolayer occurred between passages two
and three. Donor-matched air-liquid interface (ALI) epithe-
lial cultures were generated using cells at passages one or
two in PneumaCult medium (Stemcell Technologies,
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for 7, 14, or 21 days to represent various stages of
differentiation.
Stimulation of cell culture
Primary AEC from non-asthmatic donors were grown to
80% confluence and treated for 24 hours with IL-13 (10
ng/mL) alone or pre-incubated with either goat IgG isotype
control, neutralizing antibodies for IL-13Rα1 (20 μg/mL)
or IL-13Rα2 (2 μg/mL) for one hour prior to the addition
of IL-13. Primary AEC from asthmatic donors were simi-
larly grown to 80% confluence and treated for 24 hours
with IL-13 (10 ng/mL).
Pseudostratified ALI cultures of AEC isolated from
non-asthmatic donors were grown for 28 days to study
the effects of IL-13 treatment. Starting at days 14 and
21, IL-13 was added on alternate days for the duration
of two weeks and one week respectively.
Immunohistochemical analysis
Human airway tissue from asthmatic and non-asthmatic
donors and ALI cultures grown from non-asthmatic AEC
(untreated and IL-13 treated) were fixed in 10% formalin,
embedded in paraffin, and sectioned into 4 μm slices. Sec-
tions were deparaffinized in CitriSolv (Fisher Scientific,
Toronto, ON, 22-143-975) and rehydrated. Antigen re-
trieval was performed by autoclaving in Citra solution at
pH 6.0 (Life Technologies, Burlington, ON) for 22 mi-
nutes. All sections were blocked consecutively using Back-
ground Sniper (Biocare Medical, Markham, ON, B5966L)
and Dual Endogenous Block (Dako, Burlington, ON,
K5361). Sections were stained with anti-SP-D (0.25 μg/
mL), MUC5AC (1 μg/mL), or CK-5 (1 μg/mL) antibodies
using biotin-free MACH 3 AP-Polymer Detection kit (Bio-
care Medical, Markham, ON, M3U532 for mouse and
M3R533 for rabbit primary antibodies) containing alkaline
phosphatase with Warp Red Chromogen (Biocare Med-
ical, Markham, ON, WR806) as substrate. Matched iso-
type control antibodies were used as negative controls for
IHC to demonstrate antibody specificity. Hematoxylin was
used for counter-staining of the nuclei. Colour segmenta-
tion via ImagePro Plus (Media Cybernetics, Silver Spring,
MD) was performed for quantification whereby area posi-
tive was normalized to total epithelial area.
Western blot analysis
Total cell lysates collected from primary human AEC
monolayers and ALI cultures were used for Western blot
analysis according to standard techniques [21]. Twenty mi-
crograms of reduced protein samples were electrophoresed
in a 4-20% gradient SDS-PAGE gel and then transferred to
a nitrocellulose membrane. The membrane was blocked
for 1 hour at room temperature in TBST (10 mmol/L Tris-
HCl, 150 mmol/L NaCl, and 0.1% Tween-20) containing5% skimmed milk for non-phosphorylated proteins and 5%
BSA for phosphorylated proteins. The membrane was then
incubated overnight at 4°C in respective primary anti-
bodies in TBST containing 2.5% skimmed milk for non-
phosphorylated protein or 1% BSA for phosphorylated
protein. Primary antibody concentrations used were: anti-
SP-D (1:1000) and anti-p-STAT6 (1:2000) followed by re-
probing with anti-β-actin (1:2500) and STAT6 (1:1000) to
normalize for SP-D and p-STAT6 respectively. The mem-
branes were washed three times with TBST, followed
by incubation with a 1:2000 dilution of horseradish
peroxidase-labeled goat anti-mouse IgG (BD Biosci-
ences Canada, Mississauga, ON). Samples were detected
with enhanced chemiluminescence Super Signal West
Femto (Pierce, Cheshire, United Kingdom). Densitometry
was performed via ImageJ (National Institutes of Health,
Bethesda, MD) for quantification. In experiments with
multiple treatments, densitometry values for SP-D were
normalized first to β-actin and then to untreated control
to obtain fold change protein expression of SP-D.
Quantitative real time PCR
Total RNA was isolated using Trizol reagent according
to manufacturer’s protocol, and 0.6 μg of total RNA was
converted to complementary DNA (cDNA) through re-
verse transcription (RT) using qScript cDNA SuperMix
from Quanta Biosciences (Gaithersburg, MD). RT reac-
tion was incubated at 25°C for 5 minutes, 42°C for 30
minutes, and 85°C for 5 minutes. Quantitative real-
time PCR (qPCR) was performed on ABI ViiA 7 (Life
Technologies, Burlington, ON) with 20 μL reactions
containing 1 μL of cDNA, 5 μL of TaqMan master mix
(Life Technologies, Burlington, ON), and 0.5 μl of SP-
D TaqMan assay probe (Hs00358340_m1 SFTPD) or
hypoxanthine phosphoribosyltransferase (HPRT) Taq-
Man assay probe (Hs99999909_m1HPRT1) in 384-well
plates. qPCR conditions were one cycle of 50°C for 2
minutes, one enzyme activation cycle of 95°C for 10
minutes, and 40 cycles of amplification. Each amplifi-
cation cycle consists of denaturation at 95°C for 15
seconds, followed by simultaneous annealing and ex-
tension at 60°C for 1 minute. Results were analyzed with
ViiA 7 software using the comparative quantification
method where CT values of SP-D were normalized to
CT values of HPRT followed by normalization to
untreated control samples to obtain ΔΔCT = [(CTSP-D –
CTHPRT)Treated – (CTSP-D – CTHPRT)Untreated]. Expres-
sion fold change was defined as 2-ΔΔCT.
Statistical analysis
GraphPad Prism 5 (GraphPad Software, San Diego, CA)
was used for all statistical analyses. Colour segmentation
data from human airway sections and baseline ALI sec-
tions between asthmatic and non-asthmatic donors were
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from IL-13 treated ALI sections was analyzed using two-
tailed, paired t test. Data from IL-13 treated asthmatic
and non-asthmatic monolayer cultures was also analyzed
using a two-tailed, paired t-test against the respective
controls. Data from ALI cultures that differentiated from
7 to 21 days was analyzed by one-way ANOVA followed
by Bonferroni’s Multiple Comparison Test and post-test
for linear trend where appropriate. Densitometry data
from IL-13 treated non-asthmatic monolayer cultures
(with and without neutralizing antibodies) was analyzed
by one-way ANOVA with Bonferroni’s Multiple Compari-
son Test. Values are presented as mean ± SEM. Statistical
significance is defined as p-value < 0.05.
Results
SP-D expression in human airway sections
Lung tissue sections obtained from 11 asthmatic and 11
non-asthmatic donors were used to characterize the ex-
pression of SP-D in human airways. Immunohistochem-
istry was performed to study the distribution and
relative quantity of SP-D expression. Airways of both
asthmatic and non-asthmatic donors expressed SP-D
in the cytoplasm of epithelial cells (Figure 1A). WhenFigure 1 Surfactant protein D expression in human airway sections. S
and asthmatic donors via immunohistochemistry, where pink was indicative o
using colour segmentation in ImagePro Plus. Expression of SP-D in the airway
non-asthmatic donors (n = 11, t-test p = 0.004) [B].positive staining was expressed as a fraction of total
epithelial area, asthmatic airways demonstrated higher
SP-D expression (0.66 ± 0.026) compared to non-
asthmatic airways (0.50 ± 0.043) (n = 11, p = 0.004,
Figure 1B). The presence of SP-D was confirmed in
human airways and further, its expression was in-
creased in airways of asthmatics. The non-uniform in-
tensity indicates that SP-D may be expressed more in
certain subtypes of airway epithelial cells, specifically
undifferentiated basal cells.
SP-D expression in human air-liquid interface cultures
Well-differentiated twenty-one day ALI cultures of pri-
mary asthmatic AEC demonstrated higher levels of SP-D
expression compared to that of non-asthmatics as de-
tected by immunohistochemistry (fraction of total epithe-
lial area: 0.50 ± 0.08 vs. 0.25 ± 0.07, n = 5, p = 0.04,
Figure 2A, B). Western blotting also demonstrated higher
SP-D expression in ALI cultures derived from asthmatic
AEC (1.02 ± 0.15, n = 3) compared to those from non-
asthmatic AEC (0.27 ± 0.11, n = 7, p = 0.005, Figure 2C).
These findings are in concordance with those of airway
tissue sections and suggest that ALI epithelial cultures are
a viable model for studying the expression of SP-D.P-D expression was examined in sections of airways from non-asthmatic
f positivity [A]. Fraction of total epithelial area positive was quantified
epithelia of asthmatic donors was significantly higher compared to
Figure 2 Surfactant protein D expression ALI cultures. SP-D expression was examined in ALI sections grown from non-asthmatic and asthmatic
donors via immunohistochemistry, where pink was indicative of positivity [A]. Fraction of total epithelial area positive was quantified using colour
segmentation in ImagePro Plus. Expression of SP-D in the ALIs of asthmatic AEC was significantly higher compared to that of non-asthmatic
AEC (n = 5, t-test p = 0.04) [B]. SP-D protein expression in total cell lysates of ALI cultures was analyzed by Western blot. Expression of SP-D
was quantified by densitometry using ImageJ and normalized to β-actin. ALIs of asthmatic AEC demonstrated significantly higher expression
of SP-D compared to that of non-asthmatic AEC (n = 3-7, t-test p = 0.005) [C].
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ALI cultures grown from non-asthmatic AEC were ex-
posed to air and allowed to differentiate for 7, 14, and 21
days. The fraction of epithelium stained positive for SP-D
significantly decreased from 0.62 ± 0.04 at 7 days to 0.47 ±
0.09 at 14 days and to 0.23 ± 0.03 at 21 days, as detected
by immunohistochemistry (n = 5, p = 0.004, Figure 3A, B).
Similarly, the fold change of SP-D protein expression
relative to day 0 decreased from 1.68 ± 0.33 at 7 days
to 1.06 ± 0.21 at 14 days and to 0.74 ± 0.18 at 21 days
as detected by Western blotting (n = 3, Figure 3C).
While the decrease in Western blotting was not signifi-
cant, a linear trend with slope -0.5 was detected over the
two-week course from day 7 to day 21 (p = 0.04). Adding
to the finding of non-uniform staining in the airways, this
suggests that undifferentiated cells have higher expression
of SP-D.
MUC5AC, a mucin expressed in airway goblet cells, is
used here as a marker for goblet cell differentiation. Im-
munohistochemistry of ALI cultures grown from non-
asthmatic AEC demonstrated an increased expression of
MUC5AC from day 7 through 21 (fraction of total epithe-
lial area: 0.08 ± 0.02 7 days; 0.20 ± 0.06 14 days; 0.29 ±
0.05 21 days; n = 4, p = 0.007, Figure 3A and D). This indi-
cated that differentiation into mucin-secreting goblet cells
occurred in the ALI model throughout 21 days of culture.
CK-5, a marker for basal epithelial cells [3], is used to
demonstrate the extent of differentiation in ALI culturesgrown from non-asthmatic AEC. Immunohistochemistry
on these cultures demonstrated significantly reduced ex-
pression of CK-5 (fraction of total epithelial area: 0.59 ±
0.04 7 days; 0.36 ± 0.07 14 days; 0.27 ± 0.05 21 days; n = 4,
p = 0.002, Figure 3A and E). The decrease in CK-5 expres-
sion coordinate with decreased SP-D expression during
differentiation suggests that the same CK-5 positive basal
cells could potentially also be the main contributor of SP-
D production in the airway epithelium.IL-13 effect on SP-D expression
Two-week IL-13 treatment of ALI cultures grown from
non-asthmatic AEC induced characteristic changes includ-
ing altered epithelial thickness and cell type distribution
(Figure 4A). With respect to SP-D expression, IL-13 in-
duced a significant reduction in the fraction of epithelium
that stained positive for SP-D (0.21 ± 0.06) compared to
untreated (0.62 ± 0.04) as shown by immunohistochemistry
(n = 4, p = 0.0005, Figure 4B). In a time-course experiment,
IL-13 treatment of ALI cultures resulted in a fold reduction
in SP-D protein expression relative to untreated cultures as
demonstrated by Western blotting (0.65 ± 0.15 at 24 hours,
0.47 ± 0.10 at 7 days, 0.32 ± 0.06 at 14 days; n = 4-6,
Figure 4C). A significant reduction was also found in SP-D
protein expression at day 14 compared to day 7 (p < 0.05).
Due to concurrent changes in cell growth, cell type, and
epithelial structure, it is unclear whether this reduction is a
Figure 3 Surfactant protein D, Mucin 5AC and cytokeratin-5 expression in ALI cultures at different differentiation stages. SP-D, MUC5AC,
and CK-5 expression were examined in ALI sections grown for 7, 14, and 21 days from non-asthmatic donors via immunohistochemistry, where pink
was indicative of positivity [A]. Fraction of total epithelial area positive was quantified using colour segmentation in ImagePro Plus. Expression of SP-D
in the airway epithelia decreased significantly as the cultures differentiated from day (d) 7 to 21 (n = 5, one-way ANOVA p = 0.004) [B]. SP-D protein
expression in 7, 14, and 21-day ALI cultures were detected by Western blotting, quantified by densitometry relative to cultures at 0 days. A linear trend
was observed (n = 3, p = 0.04) [C]. Expression of MUC5AC in the airway epithelia increased significantly as the cultures grew from day 7 to 21 as
demonstrated by immunohistochemistry (n = 4, one-way ANOVA p = 0.007) [D]. Expression of CK-5 in the airway epithelia decreased significantly as
the cultures grew from day 7 to 21 (n = 4, one-way ANOVA p = 0.002) [E].
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induced changes in differentiation.
IL-13 regulation of SP-D in monolayer culture
To study SP-D regulation in response to IL-13, monolayer
cultures grown from non-asthmatic AEC were treated
with IL-13 (10 ng/mL) for 24 hours. When normalized tountreated control, treatment with IL-13, either alone or
after pre-incubation with IgG isotype control for 24
hours induced a reduction in SP-D mRNA (0.62 ± 0.05
and 0.60 ± 0.03 respectively, n = 3, Figure 5A). Cells pre-
incubated with IL-13Rα1 neutralizing antibody prior to
IL-13 treatment demonstrated a mitigation of the IL-13 ef-
fect on SP-D mRNA expression (0.99 ± 0.11). In contrast,
Figure 4 Surfactant protein D (SP-D) expression in non-asthmatic ALI cultures treated with IL-13. SP-D expression was examined in
IL-13-treated (10 ng/ml, 14-day duration) ALI sections grown from matched non-asthmatic donors via immunohistochemistry, where pink
was indicative of positivity [A]. Fraction of total epithelial area positive was quantified using colour segmentation in ImagePro Plus. Expression of SP-D
in the airway epithelia decreased significantly in the cultures treated with IL-13 (n = 4, t-test p = 0.0005) [B]. SP-D protein expression in ALI cultures
treated with IL-13 for 24 hours, 7 days, and 14 days were detected by Western blotting, quantified by densitometry, and normalized to untreated
control to obtain fold changes. All three durations resulted in reductions of SP-D expression (n = 6, one-way ANOVA p = 0.02) [C].
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demonstrated no significant difference in SP-D mRNA ex-
pression compared to cells pre-incubated with IgG isotype
control (0.54 ± 0.07).
Total protein lysates collected from parallel experi-
ments were analysed by Western blotting. Relative to
untreated control, treatment with IL-13, either alone or
after pre-incubation with IgG isotype control for 24
hours induced a reduction in SP-D protein (0.51 ± 0.08
and 0.65 ± 0.07 respectively, n = 6, Figure 5B). Pre-
incubation with IL-13Rα1 neutralizing antibody prior to
IL-13 demonstrated a similar mitigation of the IL-13 effect
on SP-D protein expression (0.85 ± 0.13). Pre-incubation
with IL-13Rα2 neutralizing antibody produced no signifi-
cant difference in SP-D protein expression compared to
either IL-13 treatment alone or IL-13 treatment with IgG
pre-incubation (0.60 ± 0.06).
Activation of the transcription factor STAT6 was ana-
lyzed in matched protein lysates coordinate with SP-D
expression to examine downstream activity of IL-13Rα1.
The ratio of phosphorylated STAT6 to total STAT6 as a
marker of activation was low in untreated control (0.04 ±
0.01), markedly increased in IL-13 treated cells (1.57 ± 0.27),
in IgG pre-incubated cells (1.59 ± 0.28), and in IL-13Rα2
neutralizing antibody pre-incubated cells (1.25 ± 0.17)
(n = 5, p = 0.005, Figure 5C). In contrast, pre-incubation
with IL-13Rα1 neutralizing antibody resulted in a marked
reduction in the ratio (0.52 ± 0.08).STAT6 activation, studied in ALI cultures exposed to IL-
13 for 24 hours, one week, and two weeks, was quantified
by the phosphorylated STAT6 to total STAT6 ratio. This
ratio was low in untreated ALI control (0.07 ± 0.03) and
increased in IL-13 treatment groups (n = 3, Figure 5D).
The highest ratio was observed at 24 hours (1.76 ± 0.27)
which progressively decreased at 7 days (1.27 ± 0.32) and
at 14 days (1.15 ± 0.21). This suggests that the cells contin-
ued to respond to IL-13 through IL-13Rα1 and the STAT6
pathway during the two weeks of exposure.
The effect of IL-13 on SP-D expression in asthmatic
AEC was studied in monolayer cultures and compared
with non-asthmatic AEC. Total protein lysates of untreated
and IL-13-treated (10 ng/ml) asthmatic and non-asthmatic
AEC were collected at 24 hours post-treatment and subse-
quently analysed by Western blotting. No significant differ-
ence in SP-D expression was detected in asthmatic AEC of
the IL-13 treated group relative to untreated control cells
(n = 4), whereas as significant reduction in SP-D expres-
sion was demonstrated in IL-13 treated (0.31 ± 0.06)
non-asthmatic AEC relative to untreated control cells
(0.62 ± 0.11) (n = 5, p = 0.03, Figure 5E).
Discussion
In this study, we compared the expression of SP-D in
airways of asthmatics to non-asthmatics and began to
explore what may regulate this expression. The role of
SP-D as a pattern recognition molecule in the innate
Figure 5 (See legend on next page.)
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Figure 5 SP-D expression in monolayer epithelial cultures treated by IL-13. SP-D mRNA was examined in non-asthmatic monolayer cultures
treated with IL-13 (10 ng/mL) alone and in cultures pre-treated with either goat IgG isotype control (20 μg/mL), IL-13Rα1 neutralizing antibody
(20 μg/mL), or IL-13Rα2 neutralizing antibody (2 μg/mL) one hour prior to IL-13 exposure. To obtain fold changes, ΔΔCT values were obtained by
normalizing SP-D mRNA to HPRT mRNA and normalizing treatment groups to untreated control. A significant difference was observed between
the IgG pre-treated group and IL-13Rα1 neutralizing antibody pre-treated group (n = 3, one-way ANOVA p = 0.01) [A]. SP-D protein levels in
non-asthmatic monolayer cultures under the same treatment conditions were detected via Western blotting. A significant difference was found
between the IL-13 treated group and IL-13Rα1 neutralizing antibody pre-treated group. Quantification was performed by densitometry and SP-D
protein expression was normalized to untreated control (n = 6, one-way ANOVA p = 0.04) [B]. Phosphorylated-STAT6 (pSTAT6) expression in
non-asthmatic monolayer cultures from the same experiment as panel [B] was examined via Western blotting. IL-13 treatment significantly
increased the phosphorylation of STAT6 compared to control while pre-incubation with IL-13Rα1 neutralizing antibody significantly reduced the
phosphorylation of STAT6 compared to IgG (n = 5, one-way ANOVA p = 0.005) [C]. pSTAT6 to STAT6 protein ratio in non-asthmatic ALI cultures
treated with IL-13 (10 ng/mL) over the course of two weeks show significant increases relative to untreated control (n = 3, one-way ANOVA
p = 0.001) [D]. IL-13 treatment resulted in a significant decrease in SP-D protein expression in non-asthmatic monolayer culture (n = 5, t-test
p = 0.03) whereas no significant change was detected in asthmatic monolayer culture (n = 4) [E].
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studies have demonstrated that asthma can occur subse-
quent to and be exacerbated by respiratory infections
[7-9,22,23]. More recent studies have included the innate
immune system, acknowledging that it may play import-
ant roles in the pathogenesis of asthma, affecting host
susceptibility to infections and immune response to
pathogens.
We demonstrated an elevated expression of SP-D in air-
ways of asthmatics compared to that of non-asthmatics in
lung tissue sections and ALI cultures, a model for epithelial
differentiation. The increased expression of SP-D could
arise from several possibilities: from structural differences,
such as proliferation of a cellular subtype in the epithelium,
to functional differences, such as over-production or lack
of inhibition affecting gene expression of SP-D. Previously,
Cheng et al. have shown elevated concentrations of SP-D
in the bronchial alveolar lavage (BAL) of asthmatic patients
compared to non-asthmatic controls; while a higher aver-
age concentration was found, the difference was not sig-
nificant [24]. Koopmans et al. observed increased serum
SP-D in allergic patients both at baseline and after allergen
challenge [25]. Mouse models of chronic inflammatory
conditions using P. Carinii-induced lung injury have found
7.4 fold and 71 fold increases of SP-D in BAL and serum
respectively [26]. Murine models of acute allergic lung in-
flammation have demonstrated disparity in SP-D levels in
BAL of C57BL/6 mice compared to BALB/c mice, suggest-
ing a genetic component to the baseline production of
SP-D in the lung [12].
SP-D gene deficient mice were found to exhibit hyper-
eosinophilia and increased levels of IL-5 and IL-13 upon
Aspergillus fumigatus allergen challenge, a response that
was reversible by treating the mice with SP-D [27]. As
SP-D participates in host defense and modulates inflam-
mation, an increase in SP-D levels could potentially be
beneficial if it plays a protective or even compensatory
role in asthma and other chronic inflammatory conditions.
While higher levels of SP-D in the airways of asthmaticsseem counterintuitive in the context of increased suscepti-
bility to viral infection in asthma, this suggest that under-
lying differences in the function of SP-D may exist in
humans between asthmatics and non-asthmatics. In a
study by Wang et al. purified SP-A and SP-D suppressed
Dermatophagonides pteronyssinus-stimulated lymphocyte
proliferation in naïve mice, but this suppressive effect was
reduced in sensitized mice [28]. While the study was con-
ducted in a murine model, this suggests that there may be
dysregulated processes in the immunomodulatory roles of
SP-D in sensitized patients such as those with asthma.
With regards to SP-D function, Kishore et al. have pro-
posed that SP-A and SP-D in naïve lungs can help miti-
gate potential damage from a low level of exogenous
insults; however, when overwhelmed by high levels of in-
sults, these collectins assume a pro-inflammatory role to
complement innate and adaptive immunity [29].
Immunohistochemistry of ALI cultures demonstrated
decreasing levels of SP-D expression as they differentiated
over three weeks. Visual inspection led to the observation
of SP-D in columnar cells and basal cells. Using MUC5AC
as a marker for the presence of mucin-producing goblet
cells, little to no SP-D staining was observed in goblet cells.
Previously, Madsen et al. have localized SP-D in human
lungs to alveolar type II cells, Clara cells, and on or within
alveolar macrophages [30]. Kim et al. found surfactant pro-
teins expressed in the ciliated cells of the nasal epithelium
but not the goblet cells of human nasal mucosa [31]. Here
we present novel data on characterization of SP-D within
the airway epithelia of conducting bronchus. Our observa-
tions are consistent with the previous studies with regards
to the lack of SP-D in goblet cells. Differences in SP-D ex-
pression within specific cell types could arise from the dif-
ferent regions of the respiratory tract studied.
In human airway sections, the more intense SP-D
staining in basal cells relative to the remainder of the
epithelium suggest that basal cells either produced more
or retained more SP-D within their cytoplasm. This
concurs with the observation of decreasing SP-D levels
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basal cell, visualized with CK-5 as a marker, becomes sig-
nificantly less abundant over 21 days of culture. In light of
these observations, the increased SP-D expression in air-
ways of asthmatics could be due to a greater proportion of
undifferentiated cells. The increased number of goblet
cells in asthma, which theoretically results in lower SP-D
expression, may play a relatively minor role compared to
the undifferentiated cells.
Treatment with IL-13 of non-asthmatic human airway
epithelial cells, grown in both monolayer and ALI culture,
resulted in decreased SP-D expression. Previous studies
from our laboratory have demonstrated that IL-13 treat-
ment of primary airway epithelial cells reduced spontan-
eous apoptosis in culture [32], thereby apoptosis-induced
reduction of SP-D is unlikely. Studies to date have not
come to consensus on how IL-13 modulates SP-D expres-
sion in the lungs. Haczku et al. found SP-D mRNA and
protein levels in the lungs of mice increased in response
to IL-4 and IL-13 treatment [33]. Ito and Mason found
that IL-13 reduced mRNA and protein levels of SP-D in
cultured human alveolar type II cells [34]. We have dem-
onstrated that IL-4 and IL-6 (Additional file 1; Additional
file 2: Figure S1), in addition to IL-13, all decrease SP-D
expression by non-asthmatic human AEC. This discrep-
ancy in SP-D response to IL-4 and IL-13 may be attributed
to differences in species; for instance, a non-specific
STAT-binding site is present in the SP-D promoter of rats
and mice but not that of humans [35]. In contrast to the
effect of IL-13 on non-asthmatic AEC, no significant dif-
ference was detected in SP-D expression between IL-13
treated and untreated asthmatic AEC. This suggests that
asthmatic AEC have an altered response to IL-13 with
regards to SP-D expression. This, in turn, may contribute
to the increased SP-D observed in airway epithelium of
asthmatics despite the elevated IL-13 levels in asthmatic
airways as established by several groups [18,36-38].
Potential pathways for IL-13 regulation of SP-D were
studied using monolayer cultures of human AEC. It has
been shown that monolayer cultures have the same IL-
13 receptors as ALI cultures [39]. Neutralizing anti-
bodies for IL-13Rα1 and IL-13Rα2 were used to block
the two receptors of IL-13. Data from both mRNA and
protein demonstrate that IL-13 decreased the expres-
sion of SP-D and suggest that such a reduction was me-
diated through the IL-13Rα1 pathway as opposed to
IL-13Rα2. We also demonstrated an increase in phos-
phorylated STAT6, a transcription factor downstream
of IL-13Rα1, which is coordinate with the reduction in
SP-D expression. Protein analysis of STAT6 phosphoryl-
ation affirmed that IL-13 treatment activated the STAT6
transcription factor and that this activation was to a large
degree blocked by the pre-incubation with IL-13Rα1 neu-
tralizing antibody.Studies in monolayer cultures grown from non-asthmatic
donors with exposure to IL-4 also demonstrated SP-D re-
duction and STAT6 phosphorylation. This supports the role
of the heterodimeric receptor, consisting of IL4Rα and
IL-13Rα1, in modulating SP-D levels (Additional file 1;
Additional file 2: Figure S1). Treatment of monolayer
cultures with IL-6 induced a decrease in SP-D as well
(Additional file 2: Figure S1). While IL-6 signals
through STAT3 [40], it is still possible that the path-
ways through which SP-D decreases in response to
IL-13, IL-4, and IL-6 share common components.
Study of STAT6 activation on IL-13 treated ALI cul-
tures grown from non-asthmatics demonstrated a drastic
initial increase in the expression of phosphorylated
STAT6 24 hours post-treatment followed by a gradual
decrease over the span of two weeks. The sustained de-
crease in SP-D level over the same period suggests that
the IL-13 effect on SP-D expression in non-asthmatic
AEC is chronic and sustained.
Airway epithelium differentiation and IL-13 signalling
are both implicated in the structural and functional
changes associated with asthma. Hackett et al. have
demonstrated that asthmatic patients have less differen-
tiated airway epithelium [3]. This may be a consequence
of persistent injury to the epithelium and result in an al-
tered proportion of cell types as well as their protein ex-
pression profiles. IL-13 has been shown to mediate
features of asthma independent of other cytokines in
animal models [13,16,17]. While IL-13 is closely associ-
ated with allergic asthma and adaptive immunity, it is
also valuable to know how it may affect molecules and
pathways of innate immunity in asthma.
We have demonstrated that airway epithelia of asth-
matics express more SP-D whereas non-asthmatic differ-
entiated ALI cultures have decreases in SP-D expression
in parallel with decreasing basal cells (via CK-5 marker)
and increasing goblet cells (via MUC5AC marker). IL-13
treatment, which is known to induce goblet cell hyperpla-
sia, reduced SP-D expression in non-asthmatic airway epi-
thelial cultures via IL-13Rα1 but had no effect on SP-D
expression in asthmatic airway epithelial cultures. This
suggests that in airways of asthmatics, increased SP-D pro-
duction is predominantly contributed by a less differenti-
ated phenotype, while the increased number of goblet
cells is negligible in affecting the expression of SP-D.
Additionally, IL-13 regulation of SP-D expression in asth-
matic airways was different from non-asthmatic airways,
thus contributing to the observed disparity in the SP-D ex-
pression. Asthmatic patients being more susceptible to viral
infections despite their increased SP-D expression leads
one to question whether the SP-D molecules produced in
these patients are less effective in their host defence roles.
Limitations of this study include the lack of functional
data on SP-D. While SP-D expression levels were studied
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mune response in the airways cannot be compared be-
tween people with and without asthma. Another limitation
is related to the resolution of immunohistochemistry and
the inability to clearly separate differentiated and undiffer-
entiated cells of the airway epithelium. Visual inspection
could only offer qualitative observations on the localization
of SP-D. It is difficult to compare the contribution of
SP-D expression in each cell type of the airway or in a
model exhibiting the pseudo-stratified airway epithelium.
IL-13 signalling was studied in non-asthmatic AEC at
the receptor level and any links, direct or indirect, be-
tween this and SP-D gene expression remains to be found.
Future studies on SP-D can add depth to the molecular
mechanisms in both asthmatic and non-asthmatic airways.
These can provide insight into the role SP-D plays in
asthma and sources from which dysregulation or dysfunc-
tion may arise with regards to innate immunity.Conclusion
Overall, this study demonstrated a difference in SP-D ex-
pression in airways of asthmatics relative to that of non-
asthmatics. This can have implications on the increased
susceptibility to infections and altered inflammatory re-
sponse in asthmatic patients. There could be several fac-
tors contributing to the increased SP-D levels observed in
the airway epithelium of asthmatics and further studies
are required to elucidate the underlying mechanisms. Up-
regulation of SP-D expression in asthma could be in re-
sponse to the chronic inflammatory milieu of the airways.
It may also be that SP-D molecules produced by asth-
matics do not exhibit full functionality, hence cannot me-
diate inflammation or clear pathogens, and consequently
production continues as the inflammation or infection
persists. Another potential factor could be cell type and
differentiation differences between the airway epithelium
of asthmatics and non-asthmatics. Lastly, altered regula-
tory pathways through which SP-D expression is affected,
such as IL-13, in the asthmatic airway epithelium may lead
to airway remodelling differences.Additional files
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